Mark Schlossberg Net Worth

The estimated Net Worth of Mark A Schlossberg is at least $8.18 Milion dollars as of 15 March 2022. Mr. Schlossberg owns over 60,817 units of Cytokinetics Inc stock worth over $6,915,037 and over the last 9 years he sold CYTK stock worth over $0. In addition, he makes $1,267,470 as Senior Vice President, General Counsel a Secretary at Cytokinetics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Schlossberg CYTK stock SEC Form 4 insiders trading

Mark has made over 4 trades of the Cytokinetics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 60,817 units of CYTK stock worth $648,917 on 15 March 2022.

The largest trade he's ever made was exercising 60,817 units of Cytokinetics Inc stock on 15 March 2022 worth over $648,917. On average, Mark trades about 5,040 units every 30 days since 2016. As of 15 March 2022 he still owns at least 128,604 units of Cytokinetics Inc stock.

You can see the complete history of Mr. Schlossberg stock trades at the bottom of the page.

Mark Schlossberg biography

Dr. Mark Schlossberg Esq. serves as Senior Vice President, General Counsel, Secretary of the Company. He has served as our Senior Vice President, Legal, General Counsel and Secretary since January 2019. From May 2011 to May 2018, he served as Senior Vice President, General Counsel and Corporate Secretary of Impax Laboratories, Inc. (now Amneal Pharmaceuticals, Inc.). From September 2004 to May 2011, Mr. Schlossberg served as Vice President and Associate General Counsel of Amgen Inc. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc., and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. From September 2015 until August 2017, Mr. Schlossberg served on the Board of Directors of Immunocellular Therapeutics, Ltd., a publicly traded clinical-stage company focused on the development of immune-based therapies for the treatment of brain and other cancers. Mr. Schlossberg earned a Bachelor of Sciences in business administration, finance from the University of Southern California and a Juris Doctor degree from Emory University.

What is the salary of Mark Schlossberg?

As the Senior Vice President, General Counsel a Secretary of Cytokinetics Inc, the total compensation of Mark Schlossberg at Cytokinetics Inc is $1,267,470. There are 2 executives at Cytokinetics Inc getting paid more, with Robert Blum having the highest compensation of $3,475,980.

How old is Mark Schlossberg?

Mark Schlossberg is 59, he's been the Senior Vice President, General Counsel a Secretary of Cytokinetics Inc since 2019. There are 12 older and 8 younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.

What's Mark Schlossberg's mailing address?

Mark's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.

Insiders trading at Cytokinetics Inc

Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi... a Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.

What does Cytokinetics Inc do?

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Complete history of Mr. Schlossberg stock trades at Cytokinetics Inc

Cytokinetics Inc executives and stock owners

Cytokinetics Inc executives and other stock owners filed with the SEC include:

• Robert Blum,
  President, Chief Executive Officer, Director
• Fady Malik,
  Executive Vice President - Research and Development
• Mark Schlossberg,
  Senior Vice President, General Counsel, Secretary
• Ching Jaw,
  Chief Financial Officer, Senior Vice President
• David Cragg,
  Chief Human Resource Officer, Chief Administrative Officer
• Robert I. Blum,
  CEO, Pres & Director
• Dr. Fady Ibraham Malik,
  Exec. VP of R&D
• Mark A. Schlossberg,
  Sr. VP of Legal, Gen. Counsel & Sec.
• Ching W. Jaw,
  Sr. VP & CFO
• David W. Cragg,
  Chief HR & Admin. Officer
• Leonard Patrick Gage,
  Independent Chairman of the Board
• Wendall Wierenga,
  Independent Director
• B. Lynne Parshall,
  Independent Director
• John Henderson,
  Independent Director
• Santo Costa,
  Independent Director
• Sandford Smith,
  Independent Director
• Edward Kaye,
  Independent Director
• Robert Califf,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Diane Weiser,
  IR Contact Officer
• Robert Wong,
  Chief Accounting Officer, Vice President
• Kari K. Loeser J.D.,
  VP & Chief Compliance Officer
• Robert Wong,
  VP & Chief Accounting Officer
• Jeff Lotz,
  VP of Sales & Operations
• Dr. James A. Spudich Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Bradley Paul Morgan,
  SVP Drug Discovery & Early Dev
• Caryn Gordon Mc Dowell,
  GC & Chief Compliance Officer
• Elisabeth Schnieders,
  Sr. VP, Business Development
• L Patrick Gage,
  Director
• Bonnie Charpentier,
  SVP Regulatory & Compliance
• Robert Arthur Harrington,
  Director
• Associates Vi Lp Srb,
  10% owner
• Sung Lee,
  EVP, Chief Financial Officer
• Peter S Roddy,
  SVP Finance & CAO
• Muna Bhanji,
  Director
• Michael Rabson,
  SVP Business Dev/Legal & GC
• A Grant Iii Heidrich,
  Director
• Mark Mcdade,
  Director
• Brett A Pletcher,
  EVP, Chief Legal Officer
• Sharon Barbari,
  Sr. VP, Finance & CFO
• Charles J Homcy,
  Director
• James H Sabry,
  President and CEO
• David J Jr Morgans,
  SVP-Drug Discovery and Dev
• James A Spudich,
  Director
• Michael Schmertzler,
  Director
• Jay K Trautman,
  VP, Technology
• Stephen M Dow,
  Director
• Denise Gilbert,
  Director
• Capital Ltd Portfolio Servi...,
  
• Suisse First Boston/Credit ...,
  
• John Vdomenik Stephen Lbayl...,
  
• William J Rutter,
  Director
• Ixmayfield Ix Management Ll...,
  
• Rosen Vii Affiliates Fund L...,
  10% owner
• Associates Vii Lp Srb,
  10% owner
• Associates Viii Lp Srb,
  10% owner
• Rosen Viii Affiliates Fund ...,
  10% owner
• Rosen Fund Viii Lp Sevin,
  10% owner
• Rosen Fund Vi Lp Sevin,
  10% owner
• Rosen Fund Vii Lp Sevin,
  10% owner
• Rosen Vi Affiliates Fund Lp...,
  10% owner
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Andrew Callos,
  EVP, Chief Commercial Officer